Abstract: Erythrocyte sedimentation rate (“ESR”) determinations of a patient's blood that has been combined either with blood serum from pregnant mammals or with fetal embryonic serum yield measurable results correlating well with the presence of an on-going cancer. This cancer detection method is based on differential ESR determinations and uses paired in vitro ESR tests, in which a patient's whole blood is combined with a control serum (in a control vial) comprising serum from non-pregnant mammal and with a test serum (in a test vial) comprising either fetal embryonic serum or serum from a pregnant mammal to measure differential ESR in the tested control vials. Cancer coefficient K is calculated based on the ESR measurements and is compared with a threshold value to determine whether the patient may be identified as possibly having an on-going malignancy. A kit for performing the cancer screening methodology is also provided.

Abstract: Erythrocyte sedimentation rate (“ESR”) determinations of a patient's blood that has been combined either with blood serum from pregnant mammals or with fetal embryonic serum yield measurable results correlating well with the presence of an on-going cancer. This cancer detection method based on differential ESR determinations consists of paired in vitro ESR tests, separately combining a patient's whole blood with a control serum and with a test serum comprising either fetal embryonic serum or serum from a pregnant mammal, to give a cancer coefficient value that correlates with a probability of an on-going malignancy. The probability of an on-going malignancy is determined by reference to historical data correlating the cancer coefficient and the presence of ongoing cancer. A kit for performing the cancer screening methodology is also provided.